Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020

    Research output: Contribution to journalLetterResearchpeer-review

  2. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders

    Research output: Contribution to journalLetterResearchpeer-review

  3. The impact of tobacco smoking on survival of patients with oral squamous cell carcinoma: a population-based retrospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Changing before we have to; how to mitigate disparities in pancreatic cancer care?

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Real-world data on melanoma brain metastases and survival outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Synthetic 4DCT(MRI) lung phantom generation for 4D radiotherapy and image guidance investigations

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Immune checkpoint inhibitors (ICIs) are implemented as standard treatment for patients with advanced non-small cell lung cancer (NSCLC) in first-line and subsequent-line treatment. However, certain subgroups such as patients with older age, poor performance status (PS), and severe comorbidity are underrepresented in the randomized controlled trials (RCTs). This study aimed to assess overall survival (OS), treatment data, and clinical features affecting second- or subsequent-line ICI efficacy in an unselected, Danish, nationwide NSCLC population.

METHODS: Patients with advanced NSCLC who started nivolumab or pembrolizumab as second-line or subsequent-line treatment between 1 September 2015, and 1 October 2018, were identified from institutional records of all Danish oncology departments. Clinical and treatment data were retrospectively collected. Descriptive statistics and survival analyses were performed.

RESULTS: Data were available for 840 patients; 49% females. The median age was 68 years (19% were ≥75 years), 19% had PS ≥2, and 36% had moderate to severe comorbidity. The median OS (mOS) was 12.2 months; 15.1 months and 10.0 months in females and males, respectively. The median time-to-treatment discontinuation (mTTD) and median progression-free survival (mPFS) was 3.2 and 5.2 months, respectively. Patients with PS ≥2 had a mOS of 4.5 months, mTTD of 1.1 month, and mPFS of 2.0 months. In multivariable Cox regression analysis, male sex (HR = 1.35, 95% CI 1.11-1.62), PS >0 (PS 1, HR = 1.88, 95% CI 1.52-2.33; PS ≥2, HR = 4.15, 95% CI 3.13-5.5), liver metastases (HR = 1.72, 95% CI 1.34-2.22), and bone metastases (HR = 1.27, 95% CI 1.03-1.58) were significant poor prognostic OS factors.

CONCLUSIONS: Danish real-world patients with advanced NSCLC treated with second- or subsequent-line ICI had an OS comparable to results from RCTs. Women, frail and older patients constituted a higher proportion than in previous RCTs. Clinical features associated with poor OS were male sex, PS ≥1 (in particular PS ≥2), bone-, and liver metastases.

Original languageEnglish
JournalActa Oncologica
Volume61
Issue number4
Pages (from-to)409-416
Number of pages8
ISSN0284-186X
DOIs
Publication statusPublished - Apr 2022

    Research areas

  • Cancer immunotherapy, clinical prognostic factors, immune-checkpoint inhibitors, non-small cell lung cancer, real-world evidence

ID: 70608223